Provided herein are methods for making targeted therapeutics. In several embodiments, the therapeutics are directed against soluble agents such as toxins, venoms, and/or other factors that alter physiological biopathways as well as methods of using such therapeutics to treat patients or patient populations to reduce, eliminate, or inactivate, detrimental soluble agents that such patients or patient populations have been exposed to. In several embodiments, the therapeutics are directed to patient-specific disease markers. In several embodiments, the methods comprise screening a library comprising proteins linked to their cognate mRNAs to identify mRNA-protein pairs that bind to the diseased cells, isolating one or more proteins from the identified mRNA-protein pairs, and conjugating the isolated protein(s) to a therapeutic agent.

An immunochromatography test strip for detecting pollution of diacetoxyscirpenol includes a bottom plate, where a water absorption pad, a detection pad, a gold-labeled pad and a sample pad are sequentially attached to one side of the bottom plate from top to bottom, adjacent pads are connected in an overlapping manner at a joint, the detection pad uses a nitrocellulose membrane as a base pad, a quality control line and a detection line are transversely arranged on the nitrocellulose membrane, the quality control line is coated with a rabbit antimouse polyclonal antibody, the detection line is located below the quality control line, and the detection line is coated with a diacetoxyscirpenol-ovalbumin conjugate; the gold-labeled pad is transversely spray-coated with a nanogold-labeled anti-diacetoxyscirpenol monoclonal antibody; and the anti-diacetoxyscirpenol monoclonal antibody is secreted by a hybridoma cell strain DAS5G11E7 with the preservation number of CCTCC NO.C201881.

An immunochromatography test strip for detecting pollution of diacetoxyscirpenol includes a bottom plate, where a water absorption pad, a detection pad, a gold-labeled pad and a sample pad are sequentially attached to one side of the bottom plate from top to bottom, adjacent pads are connected in an overlapping manner at a joint, the detection pad uses a nitrocellulose membrane as a base pad, a quality control line and a detection line are transversely arranged on the nitrocellulose membrane, the quality control line is coated with a rabbit antimouse polyclonal antibody, the detection line is located below the quality control line, and the detection line is coated with a diacetoxyscirpenol-ovalbumin conjugate; the gold-labeled pad is transversely spray-coated with a nanogold-labeled anti-diacetoxyscirpenol monoclonal antibody; and the anti-diacetoxyscirpenol monoclonal antibody is secreted by a hybridoma cell strain DAS5G11E7 with the preservation number of CCTCC NO.C201881.

The present invention provides a reagent comprising an antibody from which part of CH3 or CH2 in the Fc region is deleted.

The present invention provides a reagent comprising an antibody from which part of CH3 or CH2 in the Fc region is deleted.

An immunochromatography includes a concentration step of concentrating a solution capable of containing an antigen by ultrafiltration to obtain an antigen-concentrated solution; a spreading step of spreading particle composite bodies on an insoluble carrier having a reaction site at which a second binding substance capable of binding to an antigen in the antigen-concentrated solution has been immobilized, in a state where the particle composite bodies which are composite bodies of the antigen and a modified particle which is a particle modified with a first binding substance capable of binding to the antigen are formed; a capturing step of capturing the particle composite bodies at the reaction site of the insoluble carrier; and an amplification step of amplifying information of the particle composite bodies captured in the capturing step.

An immunochromatography includes a concentration step of concentrating a solution capable of containing an antigen by ultrafiltration to obtain an antigen-concentrated solution; a spreading step of spreading particle composite bodies on an insoluble carrier having a reaction site at which a second binding substance capable of binding to an antigen in the antigen-concentrated solution has been immobilized, in a state where the particle composite bodies which are composite bodies of the antigen and a modified particle which is a particle modified with a first binding substance capable of binding to the antigen are formed; a capturing step of capturing the particle composite bodies at the reaction site of the insoluble carrier; and an amplification step of amplifying information of the particle composite bodies captured in the capturing step.

This invention provides a tomato zonate spot virus detection reagent. Optimized gene encoding N protein of TZSV is expressed and purified to obtain N protein of TZSV, and two specific hybridoma cell lines are obtained, from which specific anti-TZSV monoclonal antibody could be obtained, respectively. Test strip for detecting tomato zonate spot virus is prepared with the monoclonal antibody. It is proven by experiments that the test strip of this invention is specific for TZSV, and can realize rapid detection of TZSV in leaves and other samples, with high sensitivity and convenient operation.

This invention provides a tomato zonate spot virus detection reagent. Optimized gene encoding N protein of TZSV is expressed and purified to obtain N protein of TZSV, and two specific hybridoma cell lines are obtained, from which specific anti-TZSV monoclonal antibody could be obtained, respectively. Test strip for detecting tomato zonate spot virus is prepared with the monoclonal antibody. It is proven by experiments that the test strip of this invention is specific for TZSV, and can realize rapid detection of TZSV in leaves and other samples, with high sensitivity and convenient operation.

Provided herein are biomarkers and methods for generating scores useful for assessing psoriatic arthritis (PsA) disease activity in subjects previously diagnosed with PsA. The invention also provides predictive model methods based on the biomarkers, as well as computer systems, software embodiments of the models for scoring and optionally classifying samples, and methods of recommending optimal therapeutic regimens.